• Medical_Professionals
• Medical_students
• Nurses

Dear Colleagues,

It is our pleasure to invite you to the First International Conference on Lymphocyte Engineering (ICLE 2018), set to take place in Madrid, on 13-15 September 2018.

Great strides have been made in recent years in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, pathogenic diseases and primary immune deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging field of lymphocyte engineering employs cutting edge technologies of viral and non-viral vectorology, genome editing and protein design as well as advanced clinical protocols for cell harvest, expansion and re-infusion. With groundbreaking clinical success leading to FDA approved products and with vibrant, exponentially growing research, lymphocyte engineering is the wave of the future.

Still, the challenges are formidable and the stakes are high. Realizing the full promise of lymphocyte engineering will require the combined efforts of a dedicated community. ICLE 2018 will facilitate the sharing of data and ideas, promote collaborations, and address common challenges to advance clinical translation. It will provide an effective environment for active learning, discussions of real-world case studies and for networking between like-minded peers. 

Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality.  

See you in Madrid!

On behalf of the Advisory Board,

Adi Barzel

President of the Israeli Society for Gene and Cell Therapy (ISGCT), 

ICLE conference chair, 

Senior lecturer at Tel-Aviv University

EUR

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

Participants interested in presenting an Oral or Poster presentation are invited to submit an abstract. All abstracts will undergo peer review by the Abstract Review Committee and may be accepted for Oral Presentation, Poster Presentation or rejected.

PRESENTATION TYPES AVAILABLE:

DELEGATE ORAL PRESENTATION

DELEGATE POSTER PRESENTATION

ABSTRACT TOPICS:

Genome editing for allogeneic ACT

Safety switches & controlled expression

Hematological malignancies 

Engineering HSC, NK, NKT and γδ T cells

Target & receptor discovery

Solid tumours

HIV   

Receptor and vector design  

Non-viral vectors and transposons  

Other  

GUIDELINES FOR SUBMISSION

All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university scientific publications office (or other similar facility) or by a copy editor, prior to submission.

Abstracts must be submitted via the website only.

Abstracts submitted by email will not be accepted.

Please do not submit multiple copies of the same abstract.

Abstracts must be received by the announced deadline. Please note: after the submission deadline abstracts cannot be modified or corrected.

Each person may submit up to 3 abstracts as presenting author.

All abstracts will be forwarded to the Advisory Board for review.  

The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.  There are limited oral presentation opportunities in the program, those abstracts not accepted for oral presentation will be offered a poster presentation.

You will receive confirmation that your abstract has been received, indicating the abstract number which it has been allocated. Please refer to this abstract number in all correspondence regarding this abstract.

Please contact the Conference Secretariat if you have not received confirmation that your abstract has been received.

Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by 19th June 2018 will be scheduled in the program.

Presenting author can be replaced by one of the co-authors only.

Submission of an abstract acknowledges your acceptance for the abstract to be published in the official meeting publications.

Abstracts that have been presented at another meeting may be submitted 

Notifications regarding the status of the abstract will be sent once the review process is complete.

No changes will be made to submitted and accepted abstracts

Conflicts of Interest / Disclosure: Abstract submitters will be requested to confirm that you will declare any conflict of interests in your presentation at the congress

RULES FOR SUBMISSION

Before you begin, kindly prepare the following information:

Presenting Author contact information; 

Email address

Full postal address

Daytime and evening phone number

Author and co-authors' details

Full first and family name(s)

Authors' names must be in upper and lower case (J.C.C. Smith)

Affiliation information: department, institution / hospital, city state (if relevant), country

Abstract title – Limited to 25 words in UPPER CASE

Abstract text – Limited to 300 words. We recommend using word-processing software (for example, Word) for editing your abstract and counting the number of words.

Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears. 

Use generic names of drugs. Express numbers as numerals 

You will receive an abstract reference number via email after you have submitted your abstract. 

After submitting your abstract, you can still make changes up until the deadline. 

After the deadline, no changes will be accepted.

Abstract category– abstracts must be allocated to a specific category for the scientific programme. You will need to select the category most suited to your abstract. 

ABSTRACT SUBMITTERS' DECLARATION

Disclosure of financial relationships that the author(s) may have with the manufacturer/supplier of any commercial products or services related to the work, should be indicated in the appropriate box on the abstract form. 

The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission to the Secretariat. 

The Organisers reserve the right to remove from any publications an abstract which does not comply with the above.

Abstract submission deadline 2018-05-23

We would be pleased to discuss with you and customize a package to your needs. 

To schedule a call, for more information and for bookings:

Nelly Dimitrova 

Tel: +359 2 419 8397

ndimitrova@kenes.com

Nelly Dimitrova 

Tel: +359 2 419 8397

ndimitrova@kenes.com